Figure 5.
Effect of PHLPP suppression on EGFR-TKI sensitivity in vivo. (A, B). Xenografts in nu/nu mice were generated from either HCC827-shControl (A) or HCC827-shPHLPP cells (B). Gefitinib (150mg/kg) was administered by oral gavage, and tumors volume were measured every other day. Mean tumor volumes were shown. (C) The mean residue tumor volume after 21-day course gefitinib treatment statistical testing was performed by two-sided t-test; ***P < 0.0005. (D) The log fold and absolute fold change of PHLPP mRNA from a previously study have been published from Zhang et al.